Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

Canadian Journal of Clinical Pharmacology

Volumn 16, Issue 1, 2009, Pages

  Migoya, Elizabeth M ^a   Stevens, Catherine H ^a   Bergman, Arthur J ^a   Luo, Wen Lin ^a   Lasseter, Kenneth C ^a   Dilzer, Stacy C ^b   Davies, Michael J ^a   Wagner, John A ^a   Herman, Gary A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology of Miami Inc   (United States)

Author keywords

Antihyperglycemic therapy; Dipeptidyl peptidase IV; Incretins; MK 0431; Www. Clinicaltrials.gov NCT00696826

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; KIDNEY CLEARANCE; LIVER FAILURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; CASE CONTROL STUDY; HALF LIFE TIME; HOSPITALIZATION; LIVER FUNCTION TEST; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HALF-LIFE; HEPATIC INSUFFICIENCY; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRAZINES; SEVERITY OF ILLNESS INDEX; TRIAZOLES;

EID: 63049113329     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210-5.
2. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125- 49.
3. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
4. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-61.
5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
6. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287:360-72.
7. Drucker DJ, Nauck MA. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006;368:1696-705.
8. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533-8.
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
10. Zeng W, Musson DG, Fisher AL, Wang AQ. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:1169- 75.
11. Bergman AJ, Stevens C, Zhou YY, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double- blind, randomized, placebo- controlled study in healthy male volunteers. Clin Ther 2006;28:55-72.
12. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007;81:761-767.
13. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96.